Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Physical and immunological barrier of human primary nasal epithelial cells from non-allergic and allergic donors.

Bergougnan C, Dittlein DC, Hümmer E, Riepl R, Eisenbart S, Böck D, Griesbaum L, Weigl A, Damialis A, Hartwig A, Neumann AU, Zenk J, Traidl-Hoffmann C, Gilles S.

World Allergy Organ J. 2020 Mar 9;13(3):100109. doi: 10.1016/j.waojou.2020.100109. eCollection 2020 Mar.

2.

The skin microbiome as a clinical biomarker in atopic eczema: Promises, navigation, and pitfalls.

Reiger M, Traidl-Hoffmann C, Neumann AU.

J Allergy Clin Immunol. 2020 Jan;145(1):93-96. doi: 10.1016/j.jaci.2019.11.004. No abstract available.

PMID:
31910987
3.

Pollen exposure weakens innate defense against respiratory viruses.

Gilles S, Blume C, Wimmer M, Damialis A, Meulenbroek L, Gökkaya M, Bergougnan C, Eisenbart S, Sundell N, Lindh M, Andersson LM, Dahl Å, Chaker A, Kolek F, Wagner S, Neumann AU, Akdis CA, Garssen J, Westin J, Van't Land B, Davies DE, Traidl-Hoffmann C.

Allergy. 2020 Mar;75(3):576-587. doi: 10.1111/all.14047. Epub 2019 Nov 7.

PMID:
31512243
4.

The Role of Pre-existing Cross-Reactive Central Memory CD4 T-Cells in Vaccination With Previously Unseen Influenza Strains.

Nienen M, Stervbo U, Mölder F, Kaliszczyk S, Kuchenbecker L, Gayova L, Schweiger B, Jürchott K, Hecht J, Neumann AU, Rahmann S, Westhoff T, Reinke P, Thiel A, Babel N.

Front Immunol. 2019 Apr 4;10:593. doi: 10.3389/fimmu.2019.00593. eCollection 2019.

5.

Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.

Brunner PM, Pavel AB, Khattri S, Leonard A, Malik K, Rose S, Jim On S, Vekaria AS, Traidl-Hoffmann C, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Fuentes-Duculan J, Li X, Zheng X, Estrada Y, Garcet S, Wen HC, Gonzalez J, Coats I, Cueto I, Neumann AU, Lebwohl MG, Krueger JG, Guttman-Yassky E.

J Allergy Clin Immunol. 2019 Jan;143(1):142-154. doi: 10.1016/j.jaci.2018.07.028. Epub 2018 Aug 17.

PMID:
30121291
6.

Relations between epidermal barrier dysregulation and Staphylococcus species-dominated microbiome dysbiosis in patients with atopic dermatitis.

Altunbulakli C, Reiger M, Neumann AU, Garzorz-Stark N, Fleming M, Huelpuesch C, Castro-Giner F, Eyerich K, Akdis CA, Traidl-Hoffmann C.

J Allergy Clin Immunol. 2018 Nov;142(5):1643-1647.e12. doi: 10.1016/j.jaci.2018.07.005. Epub 2018 Jul 24. No abstract available.

PMID:
30048670
7.

Differential T cell response against BK virus regulatory and structural antigens: A viral dynamics modelling approach.

Blazquez-Navarro A, Schachtner T, Stervbo U, Sefrin A, Stein M, Westhoff TH, Reinke P, Klipp E, Babel N, Neumann AU, Or-Guil M.

PLoS Comput Biol. 2018 May 10;14(5):e1005998. doi: 10.1371/journal.pcbi.1005998. eCollection 2018 May.

8.

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Guttman-Yassky E, Brunner PM, Neumann AU, Khattri S, Pavel AB, Malik K, Singer GK, Baum D, Gilleaudeau P, Sullivan-Whalen M, Rose S, Jim On S, Li X, Fuentes-Duculan J, Estrada Y, Garcet S, Traidl-Hoffmann C, Krueger JG, Lebwohl MG.

J Am Acad Dermatol. 2018 May;78(5):872-881.e6. doi: 10.1016/j.jaad.2018.01.016. Epub 2018 Jan 17.

9.

Pro-Inflammatory versus Immunomodulatory Effects of Silver Nanoparticles in the Lung: The Critical Role of Dose, Size and Surface Modification.

Alessandrini F, Vennemann A, Gschwendtner S, Neumann AU, Rothballer M, Seher T, Wimmer M, Kublik S, Traidl-Hoffmann C, Schloter M, Wiemann M, Schmidt-Weber CB.

Nanomaterials (Basel). 2017 Sep 29;7(10). pii: E300. doi: 10.3390/nano7100300.

10.

Correction: Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection.

Rose J, Emery VC, Kumar D, Asberg A, Hartmann A, Jardine AG, Bignamini AA, Humar A, Neumann AU.

PLoS Pathog. 2017 May 10;13(5):e1006386. doi: 10.1371/journal.ppat.1006386. eCollection 2017 May.

11.

Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection.

Rose J, Emery VC, Kumar D, Asberg A, Hartmann A, Jardine AG, Bignamini AA, Humar A, Neumann AU.

PLoS Pathog. 2017 Apr 13;13(4):e1006299. doi: 10.1371/journal.ppat.1006299. eCollection 2017 Apr. Erratum in: PLoS Pathog. 2017 May 10;13(5):e1006386.

12.

Highly Predictive Model for a Protective Immune Response to the A(H1N1)pdm2009 Influenza Strain after Seasonal Vaccination.

Jürchott K, Schulz AR, Bozzetti C, Pohlmann D, Stervbo U, Warth S, Mälzer JN, Waldner J, Schweiger B, Olek S, Grützkau A, Babel N, Thiel A, Neumann AU.

PLoS One. 2016 Mar 8;11(3):e0150812. doi: 10.1371/journal.pone.0150812. eCollection 2016.

13.

A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients.

Weist BJ, Wehler P, El Ahmad L, Schmueck-Henneresse M, Millward JM, Nienen M, Neumann AU, Reinke P, Babel N.

Kidney Int. 2015 Dec;88(6):1293-1303. doi: 10.1038/ki.2015.215. Epub 2015 Jul 29.

14.

Comment on "Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients".

Gorochov G, Larsen M, Parizot C, Brisson H, Nienen M, Kuchenbecker L, Babel N, Neumann AU.

Sci Transl Med. 2015 Jul 22;7(297):297le1. doi: 10.1126/scitranslmed.aab1994. No abstract available.

PMID:
26203079
15.

IMSEQ--a fast and error aware approach to immunogenetic sequence analysis.

Kuchenbecker L, Nienen M, Hecht J, Neumann AU, Babel N, Reinert K, Robinson PN.

Bioinformatics. 2015 Sep 15;31(18):2963-71. doi: 10.1093/bioinformatics/btv309. Epub 2015 May 18.

PMID:
25987567
16.

Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.

Cento V, Tontodonati M, Di Maio VC, Bellocchi MC, Valenti F, Manunta A, Fortuna S, Armenia D, Carioti L, Antonucci FP, Bertoli A, Trave F, Cacciatore P, Angelico M, Navarra P, Neumann AU, Vecchiet J, Parruti G, Babudieri S, Perno CF, Ceccherini-Silberstein F.

Dig Liver Dis. 2015 Mar;47(3):233-41. doi: 10.1016/j.dld.2014.12.004. Epub 2014 Dec 27.

PMID:
25637450
17.

Contrast-enhanced spectral mammography: Does mammography provide additional clinical benefits or can some radiation exposure be avoided?

Fallenberg EM, Dromain C, Diekmann F, Renz DM, Amer H, Ingold-Heppner B, Neumann AU, Winzer KJ, Bick U, Hamm B, Engelken F.

Breast Cancer Res Treat. 2014 Jul;146(2):371-81. doi: 10.1007/s10549-014-3023-6. Epub 2014 Jul 2.

PMID:
24986697
18.

TCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology.

Dziubianau M, Hecht J, Kuchenbecker L, Sattler A, Stervbo U, Rödelsperger C, Nickel P, Neumann AU, Robinson PN, Mundlos S, Volk HD, Thiel A, Reinke P, Babel N.

Am J Transplant. 2013 Nov;13(11):2842-54. doi: 10.1111/ajt.12431. Epub 2013 Sep 10.

19.

The genetic predisposition of natural killer cell to BK virus-associated nephropathy in renal transplant patients.

Trydzenskaya H, Juerchott K, Lachmann N, Kotsch K, Kunert K, Weist B, Schönemann C, Schindler R, Nickel P, Melzig MF, Hugo C, Thomusch O, Neumann AU, Reinke P, Babel N.

Kidney Int. 2013 Aug;84(2):359-65. doi: 10.1038/ki.2013.59. Epub 2013 Mar 13.

20.

Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.

Söderholm J, Waldenström J, Askarieh G, Pilli M, Bochud PY, Negro F, Pawlotsky JM, Zeuzem S, Ferrari C, Norkrans G, Wejstål R, Westin J, Neumann AU, Haagmans BL, Lindh M, Missale G, Hellstrand K, Lagging M.

PLoS One. 2013;8(2):e56991. doi: 10.1371/journal.pone.0056991. Epub 2013 Feb 20.

21.

Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C.

Pascarella S, Clément S, Dill MT, Conzelmann S, Lagging M, Missale G, Neumann AU, Pawlotsky JM, Zeuzem S, Rubbia-Brandt L, Bochud PY, Negro F.

Liver Int. 2013 Jan;33(1):94-103. doi: 10.1111/liv.12031. Epub 2012 Nov 14.

PMID:
23164156
22.

The role of positive feedback loops involving anti-dsDNA and anti-anti-dsDNA antibodies in autoimmune glomerulonephritis.

Arazi A, Neumann AU.

J Theor Biol. 2013 Feb 21;319:8-22. doi: 10.1016/j.jtbi.2012.09.017. Epub 2012 Nov 8.

PMID:
23142592
23.

The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.

Guedj H, Guedj J, Negro F, Lagging M, Westin J, Bochud PY, Bibert S, Neumann AU; DITTO-HCV study group.

J Viral Hepat. 2012 Jul;19(7):488-96. doi: 10.1111/j.1365-2893.2011.01569.x. Epub 2011 Dec 22.

PMID:
22676361
24.

Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study.

Bezemer G, Van Gool AR, Verheij-Hart E, Hansen BE, Lurie Y, Esteban JI, Lagging M, Negro F, Zeuzem S, Ferrari C, Pawlotsky JM, Neumann AU, Schalm SW, de Knegt RJ; DITTO-HCV Study Group.

BMC Gastroenterol. 2012 Jan 31;12:11. doi: 10.1186/1471-230X-12-11.

25.

Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation.

Wolf DG, Shimoni A, Resnick IB, Stamminger T, Neumann AU, Chou S, Efferth T, Caplan O, Rose J, Nagler A, Marschall M.

Antiviral Res. 2011 Jun;90(3):183-6. doi: 10.1016/j.antiviral.2011.03.184. Epub 2011 Apr 3.

26.

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.

Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J, Lindh M, Romero A, Missale G, Ferrari C, Neumann AU, Pawlotsky JM, Haagmans BL, Zeuzem S, Bochud PY, Hellstrand K; DITTO-HCV Study Group.

PLoS One. 2011 Feb 24;6(2):e17232. doi: 10.1371/journal.pone.0017232.

27.

Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.

Orlent H, Desombere I, Hansen B, Van Vlierberghe H, Haagmans B, De Knegt RJ, Schalm SW, Leroux-Roels G, Janssen HL; DITTO-HCV Study Group.

Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1443-8. doi: 10.1097/MEG.0b013e32833ef6e3.

PMID:
21389795
28.

IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.

Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, Missale G, Zeuzem S, Pawlotsky JM, Schalm S, Hellstrand K, Neumann AU, Lagging M.

J Hepatol. 2011 Nov;55(5):980-8. doi: 10.1016/j.jhep.2011.01.050. Epub 2011 Feb 25.

PMID:
21354446
29.

Design evaluation and optimization for models of hepatitis C viral dynamics.

Guedj J, Bazzoli C, Neumann AU, Mentré F.

Stat Med. 2011 May 10;30(10):1045-56. doi: 10.1002/sim.4191. Epub 2011 Feb 21.

30.

Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.

de Araujo ES, Dahari H, Cotler SJ, Layden TJ, Neumann AU, Melo CE, Barone AA.

J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):95-9. doi: 10.1097/QAI.0b013e3182020596.

31.

Partial immunity and vaccination for influenza.

Zhang X, Zhao Y, Neumann AU.

J Comput Biol. 2010 Dec;17(12):1689-96. doi: 10.1089/cmb.2009.0003.

PMID:
21128855
32.

Modeling immune complex-mediated autoimmune inflammation.

Arazi A, Neumann AU.

J Theor Biol. 2010 Dec 7;267(3):426-36. doi: 10.1016/j.jtbi.2010.08.033. Epub 2010 Sep 9.

PMID:
20832412
33.

Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.

Guedj J, Neumann AU.

J Theor Biol. 2010 Dec 7;267(3):330-40. doi: 10.1016/j.jtbi.2010.08.036. Epub 2010 Sep 8.

PMID:
20831874
34.

Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients.

Araújo ES, Dahari H, Neumann AU, de Paula Cavalheiro N, Melo CE, de Melo ES, Layden TJ, Cotler SJ, Barone AA.

J Viral Hepat. 2011 Apr;18(4):e52-60. doi: 10.1111/j.1365-2893.2010.01358.x.

35.

Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells.

Neumann AU, Phillips S, Levine I, Ijaz S, Dahari H, Eren R, Dagan S, Naoumov NV.

Hepatology. 2010 Sep;52(3):875-85. doi: 10.1002/hep.23778.

36.

Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.

Dahari H, Affonso de Araujo ES, Haagmans BL, Layden TJ, Cotler SJ, Barone AA, Neumann AU.

J Hepatol. 2010 Sep;53(3):460-7. doi: 10.1016/j.jhep.2010.03.019. Epub 2010 May 27.

37.

Ribavirin improves early responses to peginterferon through improved interferon signaling.

Feld JJ, Lutchman GA, Heller T, Hara K, Pfeiffer JK, Leff RD, Meek C, Rivera M, Ko M, Koh C, Rotman Y, Ghany MG, Haynes-Williams V, Neumann AU, Liang TJ, Hoofnagle JH.

Gastroenterology. 2010 Jul;139(1):154-62.e4. doi: 10.1053/j.gastro.2010.03.037. Epub 2010 Mar 17.

38.

Combining longitudinal discriminant analysis and partial area under the ROC curve to predict non-response to treatment for hepatitis C virus.

Lukasiewicz E, Gorfine M, Neumann AU, Freedman LS.

Stat Methods Med Res. 2011 Jun;20(3):275-89. doi: 10.1177/0962280209341624. Epub 2010 Mar 3. Review.

PMID:
20200199
39.

Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.

Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M; DITTO-HCV and NORDynamIC Study Groups.

Hepatology. 2010 May;51(5):1523-30. doi: 10.1002/hep.23509.

PMID:
20186843
40.

Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.

Rotman Y, Borg BB, Soza A, Feld JJ, Modi AA, Loomba R, Lutchman G, Rivera E, Doo E, Ghany MG, Heller T, Neumann AU, Liang TJ, Hoofnagle JH.

Aliment Pharmacol Ther. 2010 May;31(9):1018-27. doi: 10.1111/j.1365-2036.2010.04263.x. Epub 2010 Jan 16.

41.

In vivo dynamical interactions between CD4 Tregs, CD8 Tregs and CD4+ CD25- cells in mice.

Arazi A, Sharabi A, Zinger H, Mozes E, Neumann AU.

PLoS One. 2009 Dec 24;4(12):e8447. doi: 10.1371/journal.pone.0008447.

42.

Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.

Rozenberg L, Haagmans BL, Neumann AU, Chen G, McLaughlin M, Levy-Drummer RS, Masur H, Dewar RL, Ferenci P, Silva M, Viola MS, Polis MA, Kottilil S.

AIDS. 2009 Nov 27;23(18):2439-50. doi: 10.1097/QAD.0b013e32832ff1c0.

43.

Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment.

Lukasiewicz E, Gorfine M, Freedman LS, Pawlotsky JM, Schalm SW, Ferrari C, Zeuzem S, Neumann AU; DITTO-HCV Study Group.

J Viral Hepat. 2010 May;17(5):345-51. doi: 10.1111/j.1365-2893.2009.01183.x. Epub 2009 Sep 25.

PMID:
19780947
44.

Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.

Jain MK, Yuan HJ, Adams-Huet B, Reeck A, Shelton J, Attar N, Zhang S, Neumann AU, Carney DS, Gale M Jr, Lee WM.

J Infect Dis. 2009 Sep 15;200(6):866-76. doi: 10.1086/605475.

45.

Rapid decrease of wild-type hepatitis C virus on telaprevir treatment.

Adiwijaya BS, Hare B, Caron PR, Randle JC, Neumann AU, Reesink HW, Zeuzem S, Herrmann E.

Antivir Ther. 2009;14(4):591-5.

PMID:
19578245
46.

Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C.

Neumann AU, Pianko S, Zeuzem S, Yoshida EM, Benhamou Y, Mishan M, McHutchison JG, Pulkstenis E, Mani Subramanian G.

J Hepatol. 2009 Jul;51(1):21-8. doi: 10.1016/j.jhep.2009.01.017. Epub 2009 Mar 11.

PMID:
19447518
47.

Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection.

Burg D, Rong L, Neumann AU, Dahari H.

J Theor Biol. 2009 Aug 21;259(4):751-9. doi: 10.1016/j.jtbi.2009.04.010. Epub 2009 Apr 21.

PMID:
19389409
48.

Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.

Neumann AU, Bain VG, Yoshida EM, Patel K, Pulkstenis E, Subramanian GM.

Liver Int. 2009 Oct;29(9):1350-5. doi: 10.1111/j.1478-3231.2009.02005.x. Epub 2009 Mar 11.

PMID:
19291180
49.

A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection.

Westin J, Ydreborg M, Islam S, Alsiö A, Dhillon AP, Pawlotsky JM, Zeuzem S, Schalm SW, Ferrari C, Neumann AU, Hellstrand K, Lagging M; DITTO-HCV Study Group.

Scand J Gastroenterol. 2008 Jan;43(1):73-80.

PMID:
18938750
50.

Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy.

Pugnale P, Herrmann E, Neumann AU, Pawlotsky JM, Schalm SW, Ferrari C, Homburger Y, Zeuzem S, Negro F; DITTO-HCV Study Group.

J Hepatol. 2008 Jun;48(6):932-8. doi: 10.1016/j.jhep.2008.02.018. Epub 2008 Mar 31.

PMID:
18433918

Supplemental Content

Loading ...
Support Center